The FINANCIAL -- Novartis announced that the US Food and Drug Administration has approved Signifor injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative3.

The FINANCIAL -- GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

The FINANCIAL -- Novartis announced long-term follow-up data from the COMFORT-I and COMFORT-II Phase III studies in myelofibrosis.

The FINANCIAL -- Janssen announced that the U.S. Food and Drug Administration has approved a broader indication for the oral, once-daily medication ZYTIGA.

The FINANCIAL -- Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 in antiretroviral treatment-naive adults.